Drug Search Results
More Filters [+]

Alalevonadifloxacin

Alternative Names: alalevonadifloxacin, wck-2349, wck2349, wck 2349
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

Alalevonadifloxacin (WCK 2349) is a novel l-alanine ester prodrug of levonadifloxacin that is being developed as an oral fluoroquinolone antibiotic. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29263070/)

Mechanisms of Action: DNA Replication Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Wockhardt
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Alalevonadifloxacin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers|Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

W-2349-103

P1

Completed

Healthy Volunteers

2014-12-01

W-2349-101

P1

Completed

Other

2014-12-01

W-2349-102

P1

Completed

Healthy Volunteers

2014-12-01

W 771/2349-101

P1

Completed

Healthy Volunteers

2013-06-01

Recent News Events